Since IFN therapy is often discontinued or rescheduled due to the occurrence of flu-like reactions post-dose, Laroche et al. [17] reported that the combination of IFN and pamidronate resulted in a greater increase in bone marrow density in osteoporosis with concomitant mastocytosis. The gene discussed is IFNA1; the disease is osteoporosis.